Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183536 | 0.88 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19TSHRHPGD | |
| SCHEMBL18209663 | 0.73 | PDE4D (0.45) | CYP1A2CYP2C9CYP2C19HPGDKDM4E | |
| SCHEMBL28896549 | 0.72 | KDM4E (0.40) | HPGDKDM4EHTTALDH1A1IGF1R | |
| SCHEMBL7053250 | 0.71 | ATR (0.36) | ALDH1A1 | |
| SCHEMBL28896192 | 0.70 | KDM4E (0.39) | HPGDKDM4ESMN1; SMN2HTTALDH1A1 | |
| SCHEMBL28111801 | 0.70 | KDM4E (0.74) | TSHRHPGDKDM4EHTTALDH1A1 | |
| SCHEMBL28896742 | 0.69 | KDM4E (0.42) | CYP1A2CYP2C9HPGDKDM4EHTT | |
| SCHEMBL6835125 | 0.69 | MKNK2 (0.36) | TSHRALDH1A1LMNA | |
| SCHEMBL28896248 | 0.68 | IGF1R (0.41) | HPGDKDM4EHTTALDH1A1IGF1R | |
| SCHEMBL12495777 | 0.68 | LMNA (0.41) | CYP1A2CYP2C9CYP2C19TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6632950-B2 | By reducing the corresponding 4-nitro derivative; useful as monomers for polyamides capable of binding dsDNA (double stranded DNA) and hence in nucleotide sequence recognition | PHARMACIA CORPORATION | 2003-10-14 | — | — | US | disclosed |
| US-20020042522-A1 | Process for the preparation of derivative of 4-amino-3-hydroxypyrrole-2-carboxylic acid | PHARMACIA CORPORATION | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042522-A1 | Process for the preparation of derivative of 4-amino-3-hydroxypyrrole-2-carboxylic acid | LIG4, POLL, HPD | CYP1A2 1746/4885CYP2C9 1067/4885CYP2C19 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.